Gilead Sciences Inc. (GILD)
Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength
Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch Yeztugo, is expected to sustain growth with no major patent expiries until 2036. While oncology / immunology remain weaker segments, recent strategic M&A like CymaBay and a new CMO with oncology expertise may improve pipeline quality.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. ( GILD ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Thanks so much for attending the Jefferies Healthcare -- London Healthcare Conference. It's already day 3.
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Can Gilead Stock Outrun Regeneron In The Next Rally?
Regeneron Pharmaceuticals stock increased by 19% over the past month driven by strong third-quarter earnings and robust sales of its flagship drugs, Dupixent (for eczema and other inflammatory conditions) and Libtayo (for cancer).
Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. ( GILD ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Presentation Unknown Analyst Good morning, everyone. My name is [ Dina Elmonshed.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript
Gilead Sciences, Inc. ( GILD ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury and Investor Relations Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President of Kite Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Evan Seigerman - BMO Capital Markets Equity Research Christopher Schott - JPMorgan Chase & Co, Research Division James Shin - Deutsche Bank AG, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Tyler Van Buren - TD Cowen, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
